Physiomics PLC Interim Results Presentation (0928R)
04 Marzo 2021 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 0928R
Physiomics PLC
04 March 2021
4 March 2021
Physiomics plc
("Physiomics") or (the "Company")
Interim Results Presentation
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that the
Company's CEO, Jim Millen, will provide a live presentation
relating to its interim results for the six-month period ended 31
December 2020, via the Investor Meet Company platform, on 11 Mar
2021, at 11:00am GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event, via the
Investor Meet Company dashboard, up until 9:00am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and
register their interest in Physiomics plc, using the following
link:
https://www.investormeetcompany.com/physiomics-plc/register-investor
Investors who already follow Physiomics plc on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0) 20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKNBBOBKDCNK
(END) Dow Jones Newswires
March 04, 2021 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024